Paradigm Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Paradigm Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-37,400	Closed	-$2.92M	–	786
2014 Q3	$2.92M	Buy	+37,400	New	+$2.41M	0.41%	84

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Paradigm Asset Management's ALNY Position: Q4 2014 in Review

Paradigm Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2014, closing a stake of 37,400 shares — an estimated $2.92M sold.

Paradigm Asset Management first reported a position in ALNY in Q3 2014 and held it in 1 quarter. The position peaked at $2.92M in Q3 2014. 216 funds tracked by Wall St. Rank hold ALNY as of Q4 2014.

Paradigm Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
Paradigm Asset Management sold 37,400 Alnylam Pharmaceuticals shares in Q4 2014, an estimated $2.92M.
Paradigm Asset Management first reported a position in Alnylam Pharmaceuticals in Q3 2014 and held it in 1 quarter.
Paradigm Asset Management's Alnylam Pharmaceuticals position peaked at $2.92M in Q3 2014.
216 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2014.

Based on Paradigm Asset Management's 13F filing for Q4 2014, filed 13 Feb 2015.